Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring.
Grzegorz ProcykDominika Klimczak-TomaniakGrażyna SygitowiczMariusz TomaniakPublished in: Journal of clinical medicine (2022)
Micro-ribonucleic acids (microRNAs) are small molecules that take part in the regulation of gene expression. Their function has been extensively investigated in cardiovascular diseases (CVD). Most recently, miRNA expression levels have been suggested as potential biomarkers of platelet reactivity or response to antiplatelet therapy and tools for risk stratification for recurrence of ischemic evens. Among these, miR-126 and miR-223 have been found to be of particular interest. Despite numerous studies aimed at understanding the prognostic value of miRNA levels, no final conclusions have been drawn thus far regarding their utility in clinical practice. The aim of this review is to critically appraise the evidence on the association between miRNA expression, cardiovascular risk and on-treatment platelet reactivity as well as provide insights on future developments in the field.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- poor prognosis
- long non coding rna
- gene expression
- cell proliferation
- risk assessment
- clinical practice
- cardiovascular disease
- long noncoding rna
- binding protein
- coronary artery disease
- dna methylation
- heavy metals
- type diabetes
- atrial fibrillation
- ischemia reperfusion injury
- high resolution
- climate change
- cardiovascular risk factors